Robert Tepper - Jounce Therapeutics Independent Director
| JNCEDelisted Stock | USD 1.88 0.00 0.00% |
Director
Dr. Robert I. Tepper M.D. is the Director of the Company. Dr. Tepper is a partner at TRV, a position he has held since he cofounded TRV in 2007. From February 2013 to January 2015, Dr. Tepper served as our interim chief scientific officer. He also served as interim chief science officer of Casma Therapeutics, Inc. from May 2018 to December 2018, and of Neon Therapeutics, Inc. from October 2015 to November 2016. Dr. Tepper serves on the boards of directors of Allena Pharmaceuticals, Inc., a public biopharmaceutical company, Constellation Pharmaceuticals, Inc., a public biopharmaceutical company, and Neon Therapeutics, Inc., a public immunooncology company, and Casma Therapeutics, Inc., a private biotechnology company. Previously, Dr. Tepper served on the board of directors of bluebird bio, Inc., a public biopharmaceutical company, from September 2010 through March 2015, Kala Pharmaceuticals, Inc., a public biopharmaceutical company, from December 2009 through June 2018 and various other private life science companies. Dr. Tepper received an M.D. from Harvard Medical School and an A.B. in biochemistry from Princeton University. since 2013.
| Age | 62 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Phone | 857 259 3840 |
| Web | https://jouncetx.com |
Jounce Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1404) % which means that it has lost $0.1404 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2503) %, meaning that it created substantial loss on money invested by shareholders. Jounce Therapeutics' management efficiency ratios could be used to measure how well Jounce Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 11.89 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Jounce Therapeutics has a current ratio of 6.64, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Jounce Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Jounce Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Jounce Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Jounce to invest in growth at high rates of return. When we think about Jounce Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Vimal Vallabh | Instil Bio | N/A | |
| Myron Holubiak | Assembly Biosciences | 70 | |
| Susan Mahony | Assembly Biosciences | 52 | |
| Veena Hingarh | Instil Bio | N/A | |
| Timothy Shannon | CytomX Therapeutics | 56 | |
| John Scarlett | CytomX Therapeutics | 67 | |
| Roger Loeb | Instil Bio | N/A | |
| James Meyers | CytomX Therapeutics | 54 | |
| David Southwell | Spero Therapeutics | 56 | |
| Marion McCourt | CytomX Therapeutics | 58 | |
| Patrick Vink | Spero Therapeutics | 54 | |
| George Rohlinger | Instil Bio | N/A | |
| William Lupien | Instil Bio | 73 | |
| Matthew Young | CytomX Therapeutics | 49 | |
| Phillip Strachan | Instil Bio | N/A | |
| Vikas Goyal | Spero Therapeutics | 37 | |
| JeanFranois Formela | Spero Therapeutics | 61 | |
| Neil Exter | CytomX Therapeutics | 57 | |
| Tridibesh Mukherjee | Instil Bio | 74 | |
| Geoffrey Swier | Instil Bio | N/A | |
| Paul Newfield | Instil Bio | N/A | |
Management Performance
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 |
Jounce Therapeutics Leadership Team
Elected by the shareholders, the Jounce Therapeutics' board of directors comprises two types of representatives: Jounce Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jounce. The board's role is to monitor Jounce Therapeutics' management team and ensure that shareholders' interests are well served. Jounce Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jounce Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO Treasurer | ||
| Drew MD, Founder | ||
| Barbara Duncan, Independent Director | ||
| Luis Diaz, Director | ||
| Robert Schreiber, Founder | ||
| Padmanee MD, Founder | ||
| Drew Pardoll, Co-Founder | ||
| Louis MD, Founder | ||
| Deborah Law, Chief Scientific Officer | ||
| Elizabeth MD, Chief Officer | ||
| Richard Murray, President CEO, Director | ||
| Kimberlee Drapkin, CFO, Treasurer | ||
| Robert Kamen, Independent Director | ||
| Hugh Cole, Chief Business Officer and Head of Corporate Development | ||
| Thomas Gajewski, Co-Founder | ||
| Elizabeth Trehu, Chief Medical Officer | ||
| Robert Tepper, Independent Director | ||
| Perry Karsen, Chairman of the Board | ||
| Padmanee Sharma, Co-Founder | ||
| Cary Pfeffer, Independent Director | ||
| Duncan Higgons, Independent Director | ||
| James Allison, Co-Founder |
Jounce Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jounce Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.62) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | (82.09 M) | |||
| Shares Outstanding | 52.64 M | |||
| Shares Owned By Insiders | 15.99 % | |||
| Shares Owned By Institutions | 85.33 % | |||
| Number Of Shares Shorted | 2.02 M | |||
| Price To Earning | 10.76 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Jounce Therapeutics information on this page should be used as a complementary analysis to other Jounce Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Jounce Stock
If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |